EGFR and non-small cell lung carcinoma: To achieve active targeting of a PNPs, Patel and co-workers (2018) conjugated a monoclonal antibody (cetuximab) on the surface of DCX-loaded PLGA NPs to target the NSCLC with overexpressed epidermal growth factor receptor (EGFR) [107].